Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Genetic Mutation Found to Cause Severe COVID-19 Symptoms in Individuals

By HospiMedica International staff writers
Posted on 28 Jul 2020
Researchers have identified the gene TLR7 as an essential player in the immune response against SARS-CoV-2, suggesting that genetic factors play a key role in compromising the immune system of COVID-19 patients.

The finding with potentially major consequences for understanding and possibly treatment of COVID-19 was made by researchers at the Radboud University Medical Center (Nijmegen, The Netherlands), based on their observation of two pairs of previously healthy young brothers from two families which required mechanical ventilation at the intensive care unit (ICU) in rapid succession. More...
During the wave of COVID-19 patients that flooded Dutch hospitals in the first half of 2020, two young brothers became seriously ill with the SARS-CoV-2 virus and had to be mechanically ventilated in the ICU. One of them died from the consequences of the infection, while the other recovered. The severe course of disease in otherwise healthy young brothers was a relatively rare occurrence, especially because the virus mainly affects the elderly. This observation triggered an investigation into why these two young brothers were so severely affected.

All genes (collectively called the exome) of both brothers were sequenced, after which the investigators combed through the data searching for a possible shared cause. Their search quickly revealed mutations in the gene encoding for the Toll-like receptor 7, TLR7 for short. A few letters were missing in the genetic code of the TLR7 gene, as a result of which, the code could not be read properly and hardly any TLR7 protein was produced. The researchers then came across another pair of brothers who had fallen seriously ill with COVID-19, both of whom were also under 35 years of age and admitted in the ICU for mechanical ventilation. An investigation of the genetic code of the two brothers revealed a single spelling mistake of one DNA-letter of the TRL7 gene that led to insufficient production of functional TLR7 protein.

“TLR7 function has so far never been associated with an inborn error of immunity. But unexpectedly we now have an indication that TLR7 is essential for protection from this coronavirus,” said geneticist Alexander Hoischen. “So it seems that the virus can replicate undisturbed because the immune system does not get a message that the virus has invaded. Because TLR7, which must identify the intruder and subsequently activate the defense, is hardly present. That could be the reason for the severity of the disease in these brothers.”

“Once activated, TLR7 triggers the production of so-called interferons, signaling proteins that are essential in the defense against virus infections," said Van der Made who has investigated the consequences of improper functioning of the TLR7 receptor. “This immune response is perhaps all the more important in the fight against the SARS-CoV-2 virus, because we know from the literature that the virus has tricks to reduce the production of interferons by immune cells. When we mimic an infection with the coronavirus, we see that immune cells of the patients without properly functioning TLR7 hardly respond, and that minimal amounts of interferons are produced. These tests make it clear that the virus appears to have free rein in people without properly functioning TLR7 because it (the virus) is not recognized by the immune system.”

"This discovery not only provides us with more insight into the fundamental workings of the immune system, but it may also have important consequences for the treatment of severely ill COVID-19 patients," said Frank van de Veerdonk, immunologist and infectiologist. "The substance interferon can be given as a therapy. It is currently being investigated whether administering interferon in COVID-19 can indeed help."

Related Links:
Radboud University Medical Center


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.